Mackenzie Financial Corp Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Mackenzie Financial Corp acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 14,016 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Several other institutional investors and hedge funds also recently made changes to their positions in CPRX. Arizona State Retirement System grew its stake in shares of Catalyst Pharmaceuticals by 2.2% during the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock worth $461,000 after acquiring an additional 654 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Catalyst Pharmaceuticals by 6.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 720 shares in the last quarter. XTX Topco Ltd increased its stake in Catalyst Pharmaceuticals by 7.5% during the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 773 shares during the period. GAMMA Investing LLC raised its stake in Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 819 shares in the last quarter. Finally, Strategic Advocates LLC raised its position in shares of Catalyst Pharmaceuticals by 6.5% in the 2nd quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 864 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the sale, the insider now directly owns 675,124 shares in the company, valued at approximately $13,738,773.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the sale, the insider now owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 201,058 shares of company stock worth $4,018,188 over the last quarter. Corporate insiders own 11.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CPRX. HC Wainwright raised their price target on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Citigroup upped their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Truist Financial raised their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average price target of $29.50.

Catalyst Pharmaceuticals Trading Down 1.4 %

Catalyst Pharmaceuticals stock opened at $19.73 on Tuesday. The business’s 50 day simple moving average is $19.52 and its 200 day simple moving average is $17.11. Catalyst Pharmaceuticals, Inc. has a 12 month low of $11.89 and a 12 month high of $21.67. The company has a market cap of $2.33 billion, a price-to-earnings ratio of 36.54, a PEG ratio of 3.27 and a beta of 0.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The firm had revenue of $122.71 million for the quarter, compared to analysts’ expectations of $111.76 million. As a group, equities research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.